Titlebook: Resistance to Immunotherapeutic Antibodies in Cancer; Strategies to Overco Benjamin Bonavida Book 2013 Springer Science+Business Media New

斜谷

Unnatural Amino Acid Antibody Conjugates as Next Generation Biologics,tor mechanisms of action may provide avenues to combat resistance. The ability to encode unnatural amino acids allows unique site-specific drug conjugates as well as multispecific molecules to be made and developed against HER2-dependent tumors. This broad-based technology could potentially be applied to any antibody therapeutic target.

Regurgitation

Book 2013ntigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.

勋章

Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease provide. evidence to suggest that disease recurrence is caused by the lack of eradication of CICs by the TA-specific mAb-based immunotherapy. In addition, we will describe potential strategies to overcome this resistance mechanism which is a major obstacle to the successful application of TA-specific mAb-based immunotherapy.

态度暖昧

Trigger-Point

卜闻

LARK

Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Diseaseowever, its efficacy is limited by the lack of response in some of the treated patients and by disease recurrence. In this chapter, following a short description of the characteristics of cancer initiating cells (CICs) and the markers used for their identification in various types of cancer, we will

Libido

Overcoming Resistance to Therapeutic Antibodies by Targeting Fc Receptors,ers the prospect of increased potency through antibody engineering or adjuvant therapy. Although roles for complement and the induction of direct cell death remain controversial, the importance of Fc gamma receptors (FcγR) to the efficacy of therapeutic antibodies is irrefutable. However, the biolog

Inferior

foliage

Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Protot therapies against infectious diseases and cancer. However, the practical application of antibody-mediated therapies was only possible several decades later. Porter [155] and Edelman et al. [156] published the molecular structure of the immunoglobulin molecule and through the ingenuity of Kohler and